Biomedical subjects

Hichem Aouina

Publications and source records attributed to Hichem Aouina.

3 recordsLinked to original sources

PubMed2006

[Risk factors of side effects of antituberculosis drugs].

The aim of this study was to determine the side effects of standard antituberculosis therapy with isoniazid, rifampicin, pyrazinamide and streptomycine in patients treated for tuberculosis. One hundred eighty nine patients with proven tuberculosis, who initially received standard antituberculosis therapy, were retrospectively studied. Begaud and coll's method of side effects drugs imputability elaborated in 1999 was used in our study. Side effects related to therapy were present in 31.7% of the studied population. Gastrointestinal side effect was the most common (13.2%), isoniazid, rifampicin and pyrazinamide were often incriminated. The significant risk factors of hepatotoxicity were female gender (OR : 10.59) and concomitant hepatotoxic drugs (OR 6). Chocleovestibular toxicity was associated significantly with female gender (OR : 8.03) and diabetes mellitus (OR : 6.13). Patients aged above 50, proved to be at risk for pyrazinomide intolerance and females for streptomycine. The study did not reveal any susceptibility to isoniazid and rifadine intolerance.

Adolescent↗

PubMed2004

[Treatment of tobacco dependence: brief and intensive clinical intervention].

This article presents a literature review on the different methods of tobacco cessation that proved their efficiency through the recent meta-analyses. Smoking help cessation can consist in a systematic minimal advice that must be achieved physician or other professional of health throughout during their contact with their patients. This minimal intervention permits to get 5% of tobacco abstinence. The intensive clinical intervention is a very useful to higher dependent smokers or presenting anxiety and depressive disorders. It consists in a psychological combined approach by a behavioral and cognitive therapy and a pharmacological approach with two types of treatment: nicotine replacement therapy and the bupropion, the other "methods" not having proven their efficiency. The success rate of this intervention depends in the time of contact and the number of session. In order to promote tobacco cessation, it is necessary to widen the pharmacological product range and to educate health professionals in smoking cessation.

Anxiety↗

PubMed2002

[Smoking cessation].

We estimate that more than 80% of tobacco-smokers hope that they will stop smoking one day. The major obstacle is the psychologic and pharmacologic dependence generated by the cigarette. Different weaning methods have been tried, but their rate of success remains low. The nicotinic sustitution by transdermic track (patch) will give good results providing it is prescribed within the framework of a medical help to wean away from smoking tobacco.

Administration, Cutaneous↗